Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer

Clinical Breast Cancer

Volumn 7, Issue 9, 2007, Pages 716-718

  Bertoli, Luigi F ^a,b   Barton, James C ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SOUTHERN IRON DISORDERS CENTER   (United States)

Author keywords

Estrogen; HFE; Iron; Oral contraceptives; Phlebotomy; Tamoxifen

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HFE PROTEIN; ORAL CONTRACEPTIVE AGENT;

ADULT; ANAMNESIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IRON STORAGE; LABORATORY TEST; MASTECTOMY; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; REMISSION; SKIN BIOPSY; TREATMENT OUTCOME; VESICULAR RASH;

EID: 34548321239     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.033     Document Type: Article

References (28)

1. Kushner JFJ Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976; 58:1089-1097.
2. Bonkovsky HL, Barnard GF. The porphvrias. Gastroenterol 2000; 3:487-500.
3. Brady JJ, Jackson HA, Roberts AG, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000; 115:868-874.
4. Cruz-Rojo J, Fontanellas A, Moran-Jimenez MJ, et al. Precipitating/ aggravating factors of porphyria cutanea tarda in Spanish patients. Cell Mol Biol 2002; 48:845-852.
5. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661-1669.
6. Goerz G, Hammer G. Porphyria cutanea tarda and pregnancy. Dermatologica 1983; 166:316-318.
7. Haberman HF, Rosenberg F, Menon IA. Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens. Can Med Assoc J 1975; 113:653-655.
8. Stein KM, Raque CJ, Zeigerman JH, et al. Porphyria cutanea tarda induced by natural estrogens. A case report. Obstet Gynecol 1971; 38:755-760.
9. Agarwal R, Peters TJ, Coombes RC, et al. Tamoxifen-related porphyria cutanea tarda. Med Oncol 2002; 19:121-123.
10. Malina L, Michalikova H, Hussarova L. Porphyria cutanea tarda after antineoplastic drugs [in Czech]. Cas Lek Cesk 1999; 138:536-538.
11. Malina L, Mottl V, Michalikova H. Is tamoxifen porphyrinogenic? [in Czech]. Cas Lek Cesk 2005; 144:262-264.
12. Barton JC, Shih WW, Sawada-Hirai R, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997; 23:135-145.
13. Tannapfel A, Stolzel U, Kostler E, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001; 439:1-5.
14. Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28:404-409.
15. Lundvall O. Phlebotomy treatment of porphyria cutanea tarda. Acta Derm Venereol Suppl (Stockh) 1982; 100:107-118.
16. Kallianpur AR, Hall LD, Yadav M, et al. Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:205-212.
17. Abraham BK, Justenhoven C, Pesch B, et al. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1102-1107.
18. Acton RT, Barton JC, Snively BM, et al. Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Ethn Dis 2006; 16:815-821.
19. Gunel-Ozcan A, Alyilmaz-Bekmez S, Guler EN, et al. HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer 2006; 6:37.
20. Kondrashova TV, Neriishi K, Ban S, et al. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim Biophys Acta 2006; 1762:59-65.
21. Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932-939.
22. Manzione NC, Wolkoff AW, Sassa S. Development of porphyria cutanea tarda after treatment with cyclophosphamide. Gastroenterol 1988; 95:1119-1122.
23. Dopfer R, Doss M, Ehninger G, et al. Appearance of an inherited porphyria cutanea tarda in a child after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transpl 1986; 1:95-99.
24. Laidman PJ, Gebauer K, Trotter J. 5-Fluorouracil-induced pseudoporphyria. Aust J Med 1992; 22:385.
25. Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol 2001; 44:100-108.
26. Bulaj ZJ, Franklin MR, Phillips JD, et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med 2000; 136:482-488.
27. Arimidex® anastrozole tablets [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2005.
28. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.